full list rate price target
earn chang report pleas see
tabl page
favor dx opp
fundament driver life scienc tool diagnost group
solid foot earn updat industri confer start year
help affirm end market view outlook outlook stock
select critic oper sentiment align group strong start
line market vs see near-term
opportun diagnost coverag head earn rais
price target overweight rate well
equal weight rate quarter
rais price target quarter flu
sale good trade quarter street estim
screen reason amidst record season said believ market
miss even better invest thesi aggress flu season come
time compani sofia launch expect exceed total sofia
instal base y/i yield annuiti year
come critic new product thesi sofia menu expans drive
util per instrument time addit progress
significantli expand instal base connect virena cloud infecti
diseas tracker increas valu proposit sofia custom cannib
legaci quickvu revenu carri durabl razor/razor blade revenu stream
compani well better gross margin per kit final larger instal base
give substanti opportun cross-sel newli acquir triag platform
hospit custom believ carri signific strateg valu
last stand-alone point care oper scale left market reiter
overweight rate
believ updat start year help de-risk set-up
compani initi guidanc growth driver continu
becom larger part portfolio headwind continu shrink ngs-
relat revenu step-up y/i ad growth high
convict quantiferon-tb sustain growth aid new
relationship diasorin cover ad growth grow
qiasymphoni instal base unit y/i drive double-digit growth relat
consum contribut growth new cdx relationship fda
approv support growth person medicin ad bp growth
offset factor headwind us hpv model organ
growth overal compani believ screen conserv given
factor solid end market fundament base sampl prep
franchis differenti busi mix almost recur
revenu exposur growth person medicin continu favor
overweight rate believ execut compani
organ revenu margin improv target justifi premium valuat
compani mani mani present barclay global
healthcar confer march loew miami beach hotel
current temperatur degre make sure sign book room today
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
laboratori corp america hldg lh
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
stock price perform valuat
fundament driver life scienc tool diagnost group solid
foot earn updat industri confer start year help
affirm end market view outlook outlook stock select
critic oper sentiment align group strong start line
market vs see near-term opportun
diagnost coverag head earn rais price target
overweight rate well equal weight rate
myriad genet quarter
report includ focus look metric matter earn
season includ one-pag overview compani coverag
thought estim septemb quarter well set-up full-year
guidanc full thought end market environ pleas see
biopharma end market cro industri activ year show
increas role data integr
industri end market barclay tool industri tracker dec pmi
dx/lab end market lab trend consolid organ opp
take anoth step pama rate final directli
expect lab novemb employ trend review
lab director survey say see interest pama-driven outsourc
near-term dx trend appear posit ob/gyn survey say solid
volum adopt aesthet dx
adjust model three compani result
myriad rais estim beyond reflect higher
medicar reimburs vectra da prolari forecast revenu
million adj ep vs compani guidanc million
respect also compar prior forecast million
respect rais price target repres
adj ebitda forecast million prior price target repres
prior adj ebitda forecast million
rais forecast beyond reflect greater
visibl traction new product launch continu forecast revenu
adj ep forecast revenu adj
ep compar prior forecast respect
rais price target repres adj ebitda million
prior pt repres prior adj ebitda million
rais forecast beyond reflect greater
visibl traction sofia continu forecast revenu
million cash ep forecast revenu million
cash ep compar prior forecast million
respect rais price target repres adj
cash ebitda million also repres cash ep
prior pt repres adj ebitda million
industri confer week coverag provid updat thought
impact us tax reform oper summar chart
updat sever compani model benefit though await better
visibl re-invest offset other continu believ labcorp
quest signific beneficiari lower statutori rate agil
water screen biggest beneficiari repatri
tax reform commentari compani
datebarclaysstreetdeltabarclaysstreetdeltaagilentw fisherw scienc tool pm releas lab ghdx repres epsqdel repres epsilmn pre-announc earn n/a consensusrevenu adj adj tax rate pre-tax adj tax rate post-tax benefit tax reform expect signific charl tax reform expect broadli neutral modestli posit beyond genom big winner tax reform compani rate expect rang rate expect in-lin expect tax reform drive increment ep benefit benefit lower corpor tax rate partial off-set imposit foreign tax revenu us labcorp expect tax reform meaning posit mettler expect tax reform major posit neg myriad reform provid materi upsid move tax rate expect rang revenu us quest expect tax rate declin meaning slightli tax rate follow triage/bnp acquisit tax reform expect rate declin benefit tax reform though reduc valu nol thermo statu net beneficiari tax rate expect lower reform seen game changer cash oversea repatri provid opportun area capit alloc barclay life scienc tool diagnost
stock price perform valuat
stock perform present price
enterpris valu life scienc tool compani trade near twelv
month ntm ebitda estim compar five year averag ntm
ebitda ten year averag ntm ebitda past five year group
broadli trade within rang forward ebitda enterpris valu
diagnost compani trade ntm ebitda estim compar
five-year averag ntm ebitda ten-year averag ntm ebitda
past five year group broadli trade within rang forward
ebitda enterpris valu cro compani trade ntm ebitda
estim compar five-year averag ntm ebitda ten-year
averag ntm ebitda past five year group broadli trade within
rang forward ebitda enterpris valu lab compani
trade ntm ebitda estim compar five-year averag ntm
ebitda ten-year averag ntm ebitda past five year group
broadli trade within rang forward ebitda
recent thought agil
pleas see report
barclay ca
believ strong end market trend chemic biopharma continu
bode well agil enter biopharma believ agil healthi lc order
backlog bode well achiev msd biopharma growth chemic
upsid estim growth could serv import lever
compani model growth biopharma growth
chemic view guidanc conserv number area
set agil clear beat-and-rais path forese futur
model overal organ growth y/i high end guidanc
furthermor believ start intuvo gc cycl drive revenu
upsid annual next sever year ultivo lc similar opportun start
believ best yet come reson commerci
strategi coupl compel cascad new product launch set agil
multipl year premium top bottom line growth vs life scienc tool peer
et wednesday februari commentarybarcguidancebarcguidancechem energi growthc agil rev continu see improv variou industri datapoint importantli compani see reinvest chemic segment revenu well refin explor despit doubl digit growth last three quarter compani remain cautiou believ conserv around end market expect growth full-year compani new gc product cycl intuvo repres opportun drive better growth sever biotech growthbiopharma agil largest end market rev expect growth moder tougher comp growth growth growth tie lc lsag agil crosslab see sustain slightli organ growthour forecast emb organ growth lsag dgg agil crosslab forecast emb organ growth lsag dgg fx guidanc assum rate agil use fx hedg euro pound yen mitig ep op margincompani desir push past previou adjust oper margin target margin repres growth guidanc assum ep growth mm cffo estim repres y/i growth mm capital-expenditure forecast includ roughli complet compani new nucleic acid mm agil plan return dividend increas compani commit two tranch buyback first tranch maintain compani dilut share count million averag throughout year second tranch statementcash barclay life scienc tool diagnost
overweight agil built strong track
record reput oper perform
develop divers portfolio busi
across instrument diagnost favor
agil exposur growth biopharma
rev new product cycl ga chromatographi
opportun repatri drive upsid
improv growth chemic energi end
market due stabil trend gc product
cycl could lead better growth capit alloc
also remain opportun upsid case
reflect upsid ebitda billion
agil exposur econom activ end
market could impact growth downsid
case reflect downsid ebitda
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
reiter equal weight rate balanc improv end market trend
valuat instrument exposur compani remind
return organ growth includ beat estim
opinion result higher qualiti beat improv calid
mass spectrometri perform well nano expect appear
reason organ growth given time order convert revenu
posit european academ order trend improv three consecut
quarter manag tone around new product initi bode well
model organ growth y/i acceler versu
continu move right direct believ better visibl return
market growth need justifi recent increas multipl
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidanceeuropean academ end market commentaryapproxim revenu gener academ custom revenu europ suggest european market stabil strong order trend start importantli believ improv european fund environ normal trend though market remain soft certain countri n/an/an/an/aorgan growthdespit easi comp expect organ growth moder follow strong result compani note delay time ghz nmr sale led modest outlook revenu activ compani continu look complementari asset offer better solut custom said expect continu similar pace previou quarter build impact margin adj compani expect realiz oper margin expans compani target bp margin expans per year averag specif compani note growth portion portfolio rev gross oper margin excess compani averag forecast margin expans rate expect tax rate normal usual ep year expect back half weight mm expect continu pay dividend may announc million share repurchas author compani complet roughli repurchas said build repurchas estim guidanc assum around million share outstand statementcash barclay life scienc tool diagnost
equal weight view thesi
balanc biggest turnaround
stori life scienc tool coverag
begin see earli sign better sale
manag system drive higher earn
compani said revenu visibl
weaken remain cautiou around
execut success
expect aid new manag system
support fund environ appli
ebitda multipl upsid ebitda
million yield upsid case
execut issu fund capit purchas
drive downsid ebitda forecast
appli ebitda multipl yield downsid
case
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see report
massachusett visit
charl river set expect earn believ end market
fundament solid biotech industri fund bode well continu recent
trend import note one less sell week expect impact growth
discoveri safeti assess dsa busi adjust
day impact expect safeti assess continu high-singl digit grower
despit modest price power discoveri stabil look
busi return growth manufactur segment continu
area strength double-digit growth adjust sell day driven
microbi biolog busi research model servic rm trend
weaken believ concern relat develop market
trend compani new capac addit china expect
drive low single-digit growth overal segment
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidancerm organ growthrm view low-single-digit grower long-term growth china research model servic expect off-set weaker demand research model develop region compani new rm facil shanghai expect ship begin growth impact one less sell week lsd growerdsa organ growthdsa organ growth show modest deceler organ growth safeti assess grew high-single-digit compani remain optimist end market fundament capac remain optim level price increas expect modest discoveri result stabil dsa busi win strong support growth addit less larger tender comp improv compani believ dsa organ growth acceler impact one less sell week report revenu growth rate improv manufactur organica long-term double-digit grower driven microbi solut biolog busi impact one less sell week report revenu dd growertot organ growthon less sell week expect impact growth growth adjust week y/i organ growth expect consist sequenti organ growth growth expect stream agilux wil research brains-on-lin acquisit off-set divestitur contribut growth expect brains-on-lin contribut divestitur net river expect fx neutral revenu growth factor fx impact impli expect benefit sinc compani earn report euro yuan pound weaken yen stabl growth expect organ growth inc sell day headwind net headwind divestitur fx margin adj lt margin target includ rm dsa manufactur total compani goal consolid oper margin manag expect oper margin short long-term target due rm oper margin pressur variou staf goal ep guidanc rais account addit vc gain ep benefit vc invest stock-bas comp account charl river expect vc gain sequenti increas non-gaap tax rate mm forecast impli cffo growth mm uptick capital-expenditure invest capac preclin busi well major initi china also invest necessari busi continu becom compani repurchas share leav current author emb addit share repurchas estim compani anticip focus debt repay versu share repurchas improv flexibl pursu statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight believ charl river
biggest beneficiari biopharma wave given
leadership posit earli stage drug
discoveri research said view thesi
balanc today valuat line
charl river continu benefit favor
safeti assess compani push price
expand capac drive upsid growth
upsid case repres upsid
ebitda million
charl river exposur earli stage biopharma
research make expos fund activ dis-
leverag safeti assess busi would lead
earn compress given fix cost
downsid case repres downsid
ebitda million
recent thought agil
pleas see report
takeaway barclay
believ risk downsid genom result given lack
reimburs upsid driver risk invas breast cancer competit
genom health lower guidanc result million
revenu prior guidanc million compani provid
preliminari guidanc double-digit revenu growth million cash ebitda
similar forecast growth million cash ebitda
competit biggest concern view myriad market entri march
substanti differ vs prior threat given oncolog salesforc almost
individu coverag us payor endopredict biggest opportun
drive prostat adopt medicar reimburs expand genom
guid toward volum growth though note traction
payor critic meet guidanc favor coverag decis medicar
intermedi risk prostat start octob reiter underweight rate
price revenu estim million
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidanceinvas breast volum growthw believ oncotyp dx invas breast long-term lsd grower penetr us recent trend better due favor respons tailorx studi initi result competit repres threat watch myriad launch endopredict compani believ combin ajcc stage criteria januari tailorx intermedi result asco june help acceler global growth volum growthgrowth prostat cancer prognost test remain opportun prostat growth slow due data collect issu though compani experienc acceler genom health receiv favor coverag decis intermedi risk patient went effect octob genom health expect volum growth acceler outpac overal test growth growthintern volum growthw forecast intern volum growth would mark straight quarter double-digit volum growth addit compani gain increment coverag germani million live expect broad decis gba western europ room grow penetr compani expect begin benefit biocarti collabor infranc germani growthth compani longer issu test volum guidanc expect volum growth driven strength prostat well intern mm genom health guidanc impli revenu increas revenu estim million impli growth specif expect growth driven ramp volum expand reimburs coverag addit increas medicar price oncotyp dx follow implement pama expect drive increment million revenu growth ebitda mm compani guid greater million ebitda driven channel leverag intern growth us prostat statement barclay life scienc tool diagnost
underweight genom oper
genom test best known oncotyp dx
platform substanti revenu come
invas breast cancer prognosi despit
matur product market continu
gener neg margin ahead new product
launch see near-term opportun
remedi situat
genom health success execut
opportun dci prostat cancer
intern market see upsid share
reflect upsid revenu
competit threat core product emerg
new product launch face greater headwind
adopt expect see downsid share
reflect downsid revenu
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
thought holog
pleas see report
check box
cyno in-lin
note weve updat
model reflect holog
announc updat
provid financi updat ahead competitor industri
confer see sever posit affirm convict thesi first
deliv quarterli revenu million better forecast
guidanc midpoint million result balanc across
busi segment compani note better perform breast health molecular
diagnost intern result impli compani deliv organ growth
adjust sell day view strong result second cynosur
stabil deliv in-lin revenu million believ help show
bottom salesforc contribut new product help
compani achiev double-digit growth third compani highlight
major beneficiari tax reform new effect rate
vs prior guidanc continu view valuat compel context
solid result busi fundament reiter overweight rate
et thursday februari commentarybarcguidancebarcguidancebreast organ growth model increas servic growth product revenu keep mind one less sell week addit rnsa breast confer take place decemb make season weak quarter compani surpass penetr instal base tone around placement opp conserv said believ new instrument low high end help elast demand servic revenu remain signific opportun growth share gain convers cycl price premium expect lsd growth also driven affirm brevera revenu prelim growthdiagnost organ growth growth led mdx dx total model forecast assum deeper panther penetr expans well opportun expand menu viral load respiratori area model declin cytolog growth driven impact less sell day new uspstf draft guidelin cervic cancer screen risk final continu watch expect million contribut blood screen busi prelim growth ex blood screen gyn surgic organ growth model msd organ growth organ declin novasur growth myosur view conserv expect novasur growth moder follow lap compet product discontinu expect upsid target driven strength intern new product prelim growthmed aesthet revenu improv sequenti remain y/i due challeng comp inclus view cynosur long-term double-digit grower improv salesforc product new product launch consum growth cross-sel opportun improv convict sustain growth prelim growth growthin earli compani hire four new region commerci leader drive better growth segment sale acceler organ growth y/i respect growth driven gain european breast panther placement gyn surgic cynosur n/an/an/an/aorgan guidanc face headwind sell day growth lose day gain organ growth expect impact day impact op margin model ebit margin due neg mix impact blood screen divestitur cynosur growth model net growth cynosur less blood screen acquisit growth base preliminari releas preliminari revenu result compani provid updat ep preliminari revenu tax reform guidanc updat ep deploy ttm leverag follow divestitur subsequ acquisit expect leverag net debt ebitda exit incur addit debt cynosur acquisit fund proce blood screen divestitur tuck-in still possibl coupl repurchas outstand mm emb debt repay forecast repres revenu repurchas repres upsid stmtcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ grow
stronger longer driven longer
mammographi tail mdx growth panther
myosur tuck-in new product launch
could drive modest upsid revenu
mdx gyn surgic busi continu
drive outsiz growth new product launch
add modestli growth upsid case
reflect upsid earn power
penetr rate us mammographi
busi slow faster expect downsid
case reflect downsid earn
power
full thought icon
guidanc pleas see
note icon plc
oper visibl start
januari icon issu initi guidanc screen in-lin
revenu forecast modestli better midpoint ep believ expect
appear reason help set tone cro oper good foot
start new year notabl revenu guidanc billion came roughli
estim street midpoint ep came
better forecast better street revenu growth
estim includ tailwind fx compani quot constant currenc
growth well tailwind mapi acquisit juli impli
organ growth consist forecast compani
continu expect custom concentr moder
roughli revenu impli
revenu declin around y/i icon expect execut
backlog drive total compani growth guidanc improv visibl
compani turn corner toward better growth
note weve updat model reflect guidanc
et thursday februari commentarybarcguidancebarcguidancegross ordersgross award lumpi model growth impli growth greater outsourc market share gain manag note budget continu strong level outsourc increas year-to-d gross order y/i improv visibl acceler revenu elev level cancel assum cancel rate return normal level icon cancel rate respect burn ratew model revenu burn decreas assum greater specialti mix coupl cancel weigh revenu burn model stabliz icon burn rate growtha trial continu wind expect organ growth begin inflect start continu support strength recent book growthw assum clinic rm annual late mapi close acquisit add growth expect mapi acquisit add growth compani guid toward fx tailwind impli tailwind growthon icon re-affirmed revenu guidanc said weaker organ growth expect off-set favor fx margin adj inc amort icon lead margin amongst driven compani effici manag workforc said manag still see upsid opportun sg enhanc expect margin ramp revenu icon recov earn icon rais ep guidanc midpoint emb repurchas forecast repres revenu repurchas share leav remain compani share repurchas author remind addit share repurchas includ guidanc statementcash price
equal weight icon success
transit nich european cro
becom intern top-tier cro recent result
show compani grow expect
headwind largest custom said
think compani need activ data
integr industri lead margin also impli
less room upsid
icon exhibit signific growth margin
expans improv custom diversif
would improv sentiment icon futur prospect
upsid case repres
upsid ebitda million
revenu concentr could continu
repres headwind overal growth similarli
industri cancel issu could continu begin
weigh icon growth margin downsid
case repres downsid
ebitda million
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see report
mid-term target
follow compani analyst day believ critic year
iqvia show acceler revenu growth demonstr integr
data strategi reson client proof iqvia
million increment award result differenti offer
believ potenti disrupt strategi one sever factor could drive
recent uptick cro industri consolid believ success
reflect backlog growth new busi win start uptick revenu
first award combin offer given iqvia issu
long-term revenu growth guidanc msd would expect initi guidanc
conserv view compani drive upsid target prove
success strategi would posit sentiment continu share repurchas
remain author execut cost synergi
like use lever earn line
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidanc net auth ttm mm three chang new business/backlog calcul includ report ttm basi book contract compani integr strategi clearli begun reson custom sinc merger compani attribut million award data end backlog forecast step-up net new author less revenue net book-to-bil ttm mm expect book-to-bil though quarterli result lumpi upsid driven market share gain believ merger integr risk subsid expect book-to-bil rev mm expect acceler revenu report growth embed organ revenu mm follow merger portion revenu re-seg commerci solut estim emb organ growth headwind fx report june note compani evalu sale busi higher level new drug approv would expect busi return growth solut mm revenu estim emb tailwind fx headwind encor divestitur organ growth juli compani sold encor busi drag growth year-to-d growth forecast organ growth solut declin integr engag servic growth commerci solut model fx tailwind sinc earn euro yuan pound weaken yen remain flat iqvia well-hedg earn growthth compani expect revenu continu ramp growth rate base pro-forma marginexpect cost synergi run-rat million epson manag rais ep guidanc midpoint model tax rate anticip earn growth lead cash ep capital-expenditure forecast repres increas buy-back author may compani million remain current author addit buyback embed estim compani announc repurchas share sell statementcash industri view neutral
overweight believ iqvia creat
best class platform cro industri believ
marri quintil cro platform im clinic
insight yield market share gain time
earn growth
believ iqvia valu proposit could yield
market share gain time coupl long
runway cost synergi upsid case
repres upsid adj ebitda
risk around integr recent growth
trend integr engag solut
busi could weigh near-term growth
downsid case repres downsid
adj ebitda billion
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see report
thesi depend long-
maintain equal weight rate believ still earli make
definit call thesi long-term need greater convict novaseq
expand market high-throughput sequenc vs simpli drive replac cycl
order justifi long-term growth aspir valuat announc
novaseq instal base exit stand roughli line forecast
driven consist placement q/q compani continu see multi-year upgrad
cycl ahead novaseq note hiseq custom upgrad
new platform far acceler consum growth also
import indic demand elast reiter equal weight rate
thesi continu look greater convict long-term growth order
note updat model reflect compani result guidanc
et tuesday januari commentarybarcguidancebarcguidancenovaseq placementsillumina launch new high-throughput sequenc whole genom applic forese futur believ commentari around novaseq launch import driver stock far feedback strong compani ship instrument forecast placement placement placement annual beyond model consum pull-through instal basewith introduct novaseq cannib hiseq placement expect custom recent purchas option upgrad novaseq illumina plan target activ hiseq user first assum approxim novaseq placement replac expect net hiseq remov instal base consum growth consum grew y/i driven increas util high-throughput system novaseq well better-than-expect nextseq perform strong consum growth expect inventori burndown hiseq famili off-set increas novaseq consum demand instrument growthw expect trend begin normal favor comp upsid potenti novaseq growtharray growth driven rise popular fo consum genom expect growth slow comp becom growthour organ growth forecast emb acceler conum instrument guidanc assum fx rate octob growthillumina guidanc top-lin growth y/i includ ramp consum instrument growth driven meaning novaseq revenu contribut fx expect neutral rev ex-comp expect continu compris signific portion budget said forecast repres declin margin adj forecast oper margin increas y/i forecast oper margin non-gaap ep guidanc includ impact tax reform helix statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight leader next
gener sequenc market
project growth
posit fundament
impress compani abil transform
genom market believ sentiment well
reflect share
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ebitda billion
given pace innov cycl next
gener sequenc believ still
earli declar instrument choic
clinic use downsid case reflect
downsid ebitda million
focu labcorp set guidanc look
continu strength lab oper inflect cro growth updat
strategi improv margin covanc addit compani provid updat
tax reform repres signific opportun given compani tax
rate diagnost rev expect organ volum trend remain strong
model volum growth driven recent lab acquisit
underli util favor weather comp revenue-per-
req despit deflationari price pama expect improv
driven posit mix toward genom esoter test covanc
rev strong book help improv visibl businesss expect organ
revenu growth ramp labcorp host investor day
provid addit strateg updat compani valu combin
lab cro oper togeth labcorp top pick believ valuat
compel ebitda
et tuesday februari commentarybarcguidancebarcguidancelcd volum model organ volum aid acquir volum organ includ underli util easier comp due hurrican matthew model organ volum acquir volum organ includ underli util weather easier hurrican pricefast growth genomic/esoter test push price higher plu mix benefit sqnm annual notabl expect pama headwind total rev-per-req lab busi partial offset mix benefit price result expect increas organ adj op margin estim impli y/i forecast y/i compani remain track achiev goal million launchpad save labcorp believ on-going save opportun lcd segment beyond net book-to-billwhil covanc revenu growth weaker ytd book strong book-to-bil respect stronger book bode well revenu organ growthfollow weaker growth ytd expect covanc revenu modestli improv infect revenu impact cancel two larg clinic studi late labcorp provid central laboratori studi two studi annual addit slower revenu convers pre-clin clinic segment headwind long-term view covanc msd organ grower strong book ytd support adj op margin model oper margin expans respect result effici initi well better anticip revenu growth earn manag note acheiv million cost synergi includ complet central lab consolid manag also recent introduc covanc launchpad program first phase expect drive million save million annual basi earn labcorp maintain anticip fx headwind impli headwind growth emb contribut chiltern mt sinai paml transact transact expect contribut growth epson manag rais guidanc midpoint reflect chiltern accret partial off-set impact hurrican quarter assum cut medicar revenu lab revenu anticip pama roughli headwind ep mm reinstat share repurchas program labcorp repurchas author remain remind complet repurchas includ mm forecast repres revenu line statementcash barclay life scienc tool diagnost
laboratori corp america hldg lh
overweight labcorp remark track
record execut led lead organ
growth augment value-enhanc
acquisit covanc acquisit continu
theme expect expertis
organ posit labcorp premier
partner choic companion diagnost play
greater role clinic decis make
labcorp integr strategi covanc yield
higher sustain growth profil compani
addit lab industri consolid lead
acceelr revenu ep growth upsid
case reflect upsid ep
reimburs headwind congression
action oner clinic lab
hospit begin greater penetr esoter test
volum downsid case reflect
downsid ebitda billion
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see report
consist compound
rich multipl initi equal
set-up somewhat de-risk given compani
provid guidanc earn look opportun could
acceler mettler toledo growth potenti near term order justifi
valuat remind growth acceler late broad-bas strength asid
food retail said guid deceler organ growth
in-lin histor norm model organ growth follow
specif growth trend core industri product inspect
expect slow compani note end market remain strong
caution remain limit room improv howev better expect
growth end market could drive upsid stock ultim believ
revers organ growth closer peer level may put pressur valuat
alreadi repres consider premium peer
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidancelab organ growthth lab segment hsd grower last year strong demand biopharma custom compani continu view biopharma market attract expect growth rate moder unual high level respons forecast good growth lab busi growth industri organ growth industri rebound follow slower growth previou year particular pent-up demand china major growth driver though result europ america also solid compani forecast solid growth segment growth product inspect organ growthproduct inspect demand remain strong given rise standard food qualiti around world domin player market share next competitor emerg market present opportun strong growth compani expect growth product inspect declin given tough comp time growth food retail organ growthresult volatil includ organ declin segment meaning slower growth segment compani manag profit growth growth china organ growthchina continu strongest market meaning growth across product line specif benefit shift resourc faster grow area chines demand continu robust compani guid msd growth due tougher comp growthw forecast normal organ growth expect serv tailwind growthth biotix acquisit expect contribut growth margin adj guid oper margin increas margin expans driven organ growth price suppli chain initi annual price increas roughli better tool rais ep guidanc midpoint due solid result favor fx environ forecast buy-back statementcash barclay life scienc tool diagnost
equal weight market leader
precis weigh analyt instrument
compani dispar custom base allow
differenti unit price time consist free
cash flow deploy toward tuck-in
share repurchas biggest near-term risk
relat valuat share screen rich
opinion
better execut end market perform drive
upsid ebitda forecast re-rat
ev/ebitda multipl gener upsid
case
macro pressur end market perform drive
downsid ebitda forecast
valuat re-rat ev/ebitda multipl
gener downsid case
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
thought riskscor
pleas see report
adopt aesthet
thought genesight
pleas see report
show posit
may
believ near-term setup screen posit myriad genet rais
price specif recent fda approv bracanalysi
cdx astrazeneca lynparza metastat breast cancer open substanti volum
opportun hereditari cancer test hct myriad estim preval pool
women newli elig test increment incid pool
patient add long-term durabl opportun addit myriad focus drive hct
volum riskscor launch substanti opportun prevent test
final implement pama carri reimburs tailwind vectra da
price per test vs previous prolari vs previous said
maintain equal weight rate myriad believ reimburs coverag
new product critic justifi acceler earn growth valuat
model ep acceler
base case model assum measur ramp reimburs
coverag time though arduou process payor negoti reduc visibl
achiev ramp ultim need convict manag care
reimburs new product order justifi valuat thesi
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidancehct revenu declin give us paus wait baselin model revenu declin y/i genesight revenu mm myriad shown impress volum growth genesight penetr psych channel model pro-forma volum growth moder larg number growth primari driver pro-forma revenu growth revenu mm favor intermedi risk medicar coverag began septemb believ could act catalyst addit commerci payor coverag model price increas reflect increas medicar rate expect prolari volum increas addit payor upsid could come nccn updat da revenu mm volum increas sequenti last four quarter stabil salesforc expect volum revenu improv model increas price new medicar rate myriad could see addit upsid vectra includ american colleg rheumatolog acr revenu mm outsid product describ endopredict repres notabl opportun myriad establish coverag payor growth model organ declin includ return organ growth growth genesight contribut quarter acquir growth margin adj payor coverag top line leverag critic improv elev initi expect gener million save includ million forecasct op marg rateth compani guid tax rate anthem out-of-coverag decis neg impact ep point refer compani note contract unitedhealth genesight would increas ep compani priorit debt repay near-term use cash myriad expect fulli paid balanc credit facil end said management indic would buy-back share statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight
crossroad look manag
competit concern hereditari cancer test
drive growth new product view
thesi balanc point
expect revenu acceler new product
launch carri greater increment margin
commerci upsid case
reflect upsid ep
myriad face new competit hereditari
cancer test commerci new product
face rigor review payor downsid
case reflect multipl downsid
ep
rel tool brethren continu believ near-term growth profil
laggard head earn concern
discoveri analyt solut da segment rev grow
exposur diagnost compani clearli tri address growth issu
recent major announc acquisit euroimmun addit
emerg market diagnost food/environment end market new product
contribut nice top line rebound follow soft result
compani guid organ growth rel differenti
lack biopharma product asset peer drive excess growth
addit core industri exposur isnt differenti catch outsiz tailwind
global recoveri lean emerg market diagnost
avenu drive better perform ultim view share fulli valu trade
ebitda estim cautiou around valuat
et thursday januari commentarybarcguidancebarcguidancediagnost organ growthgrowth expect driven screen busi includ newborn infecti diseas test well comapni recent announc genet inti emerg market expect drive faster long-term growth tulip acquisit increas exposur india acquisit euroimmun close compani presenc autoimmun allergi diagnost em analyt solut da organ growth expect recent improv industri academ end market continu food safeti expect acceler tailwind increas regul china manag anticip slowdown biopharma market though growth broadli lag tool peer growthour forecast impli improv y/i adjust day recent strengthen usd anticip fx serva tailwind growth complet sale medic imag busi may medic imag sale million revenu headwind expect off-set million contribut acquisit tulip diagnost euroimmun acquisit close decemb overal forecast acquir growth margin adj target oper margin nearer term divestitur medic imag weigh margin given higher margin profil busi said oper margin forecast impli improv growth impact headwind medic imag mm expect continu pay quarterli dividend per mm given recent acquisit euroimmun billion would expect repurchas activ statementcash barclay life scienc tool diagnost
underweight compel
portfolio nich product across environment
human health long-term outlook
organ growth margin improv
compel believ share
range-bound near term get better
visibl emerg market revenu
opportun china nucleic acid test
newborn screen drive upsid
ebitda forecast upsid ebitda
million yield upsid case
emerg market fx remain pressur drive
downsid estim
downsid ebitda million yield downsid
case
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see report
growth health
pleas see report
growth data initi
health offer differenti growth profil among public cro group
therefor result guidanc import compani
send messag outlook continu trend believ strong
recent net new busi award ttm improv visibl double-digit organ
revenu growth remind health known one
partnership notabl takeda announc partnership expect
continu increment contribut view symphoni health
transact close strateg sound way improv compani data
valu proposit expect updat focu integr context
compani industry-lead growth profil view valuat attract
ebitda reiter overweight rate
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidancegross order model flat gross order growth result difficult comp project growth emb growth greater outsourc market share gain look back abl consist outgrow peer compani continu execut level would expect drive upsid number cancel begin backlog anticip cancel rate histor cancel rang burn ratea clinic trial becom increasingli complex revenu burn rate decreas across cro industri model burn rate y/i model y/i view rel high backlog burn rate reflect strong execut conserv backlog research revenu mm clinic research segment compris legaci oper solut revenu mm data solut busi compris acquir symphoni busi close guid low-teen growth growth organ growthw believ strong recent busi award put compani good foot achiev sustain double-digit revenu growth symphoni data solut segment begin contribut organ growth howev growth rate similar clinic research segment inclus materi impact organ growthth symphoni acquisit contribut acquir growth partial model fx tailwind neutral impact usd revenu exposur cost exposur guidanc assum euro pound exchang rate respect expect growth consist organ growth contribut symphoni epson due lower tax rate expect favor fx symphoni transact manag rais ep guidanc midpoint model adj tax rate slightli guidanc expect earn leverag come primarili sg line hire ahead new busi limit gross margin capital-expenditure forecast repres revenu y/i would expect focu debt repay near term flowincom statement barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight health lead cro
focus late stage clinic develop
believ approach data util clinic trial
posit well increas demand
biopharma sponsor augment recent
acquisit symphoni health view valuat
attract context health market-
combin better clinic research growth
augment new data capabl drive
upsid ebitda forecast upsid case
repres upsid ebitda
weaker growth matur strateg partnership
could limit upsid organ growth margin
expans downsid case repres
downsid ebitda million
latest thought
thesi pleas see
report
report
settlement oxfd
believ updat start year help de-risk set-up
compani initi guidanc growth driver continu becom larger
part portfolio headwind continu shrink notabl highlight
ngs-relat revenu step-up y/i ad
growth high convict quantiferon-tb sustain growth
aid new relationship diasorin cover ad growth
model establish goal addit qiasymphoni placement
believ double-digit growth relat consum contribut
growth new cdx relationship fda approv support growth person
medicin ad bp growth offset factor headwind us
hpv exit overal sale model organ growth
overal compani believ could prove conserv given factor
solid end market fundament base sampl prep franchis
differenti busi mix almost recur revenu exposur growth
person medicin continu favor overweight rate
believ execut compani organ revenu growth ramp margin
improv target justifi premium valuat stock
date report wed januari conf call et thur februri commentarybarcguidancebarcguidancequantiferon growth rev quantiferon continu grow cer driven convers legaci tst test support updat guidelin uspstf launch gen test target revenue symphoni base rev expand instal base drive consum growth placement opp benefit continu expans menu abroad us system found nich custom run ldt annual pull-through per instrument roughli announc placement exceed novemb cumul reach target placement generead begun contribut modestli organ growth estim annual pull-through per instrument compani includ formal guidanc placement long term goal market share benchtop total revenu expect grow growth emb growth academ growth mdx pharma appli forecast growth academ growth mdx growth pharma growth appli mdx growth driven quantiferon qiasymphoni generead overal end market demand compani sampl prep portfolio compani guid toward fx tailwind revenu neutral ep impact expect fx tailwind revenu growth divest growthin emb net headwind omicsoft acquisit contribut off-set recent china mdx divestitur remind exiqon acquisit annual late june china mdx divestitur expect headwind ebit margin compani optimist restructur activ contribut oper margin improv compani expect realiz least improv anticip improv guidanc adj ep exclud after-tax restructur charg expect non-gaap tax rate versu previou guidanc forecast impli revenu mm return thru synthet share repurchas complet januari complet repurchas statement barclay life scienc tool diagnost
overweight reach inflect
point serv baselin
acceler growth molecular diagnost look
forward leadership companion
diagnost develop next gener
sequenc capabl give us visibl
million near-term revenu opportun
number avenu growth
give investor better visibl revenu growth
upsid case reflect upsid
ep
price competit diagnost pressur
result estim come guidanc
expect downsid case reflect
downsid ep
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
pleas see report
pama cut lower lt
view expect
key focu quest setup combin industri
consolid reimburs pressur pama impact ep growth
remain cautiou quest current growth trajectori ep growth includ
pama headwind thesi depend peer consolid hit
long-term target mid-to-high singl digit earn growth watch
trend close inflect hospit outsourc addit major
beneficiari tax reform anticip detail impact compani
earn growth trajectori go forward recent announc contribut
earlier deal put quest good foot hit acquir growth
believ magnitud need increas fulli off-set pama near
term underli lab volum stronger recent histori driven growth
genom test forecast volum growth organ
acquir growth like set-up earn believ
guidanc import updat earn
et thursday februari commentarybarcguidancebarcguidancevolum forecast includ organ growth acquisit peacehealth outreach fusion/clearpoint cchc hartford healthcar cla cleveland heartlab shiel within organ growth model underli util tailwind easier comp due hurrican matthew benefit pl montefior peacehealth forecast includ organ acquir growth organ model util new busi tailwind easier comp hurrican harvey/irma per requisitionunderli rev-per-req posit driven mix faster growth genomic/esoter test notabl price chang icar though unit cost remain headwind addit pl arrang mix headwind price given lower revenue per req notabl expect pama headwind total rev-per-req offset mix benefit drive expect declin organ growthlong-term guidanc assum equival growth includ pl arrang growthquest lt guidanc assum acquir growth annual embed number peacehealth fusion/clearpoint cchc hartford healthcar cla cleveland heartlab shiel transact carry-ov acquisit put quest good foot hit target growthlong-term guidanc assum revenu growth compound-annual-growth-rate emb organ growth acquisit guidanc includ tailwind un-announc lab acquisit despit upcom headwind pama quest remain commit long-term margin ex-amort manag note million target invigor save quest work optum number initi includ reduc paper requisit manag bad debt effici compani also focus greater autom site consolid go quest believ on-going opportun improv effici ex-amort manag lower ep guidanc midpoint reflect hurrican impact well small on-going impact off-set contribut acquisit tax benefit relat stock-bas comp assum cut icar revenu total anticip pama roughli headwind ep context pama quest guid ep rang mm result compani rais cffo guidanc mm forecast repres revenu flat increas per share mm quest billion remain current share repurchas author emb repurchas statementcash barclay life scienc tool diagnost
equal weight thesi quest rel
balanc compani financi flexibl
leverag scale deploy capit peer
said quest may need play catch-up
strateg integr solut across
clinic research clinic test
deploy capit better-than-expect
margin improv would repres upsid
estim upsid case reflect
upsid ebitda billion
reimburs headwind congression
action oner clinic lab hospit
penetr esoter test volum increas
downsid case reflect downsid ebitda
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
recent thought
thesi pleas see
report
corp fire
cylind
pleas also see report
detail bnp disput
provid new clariti thesi
rais price target quarter flu
sale good trade quarter street estim screen
reason amidst record season said believ market miss even
better invest thesi aggress flu season come time sofia
launch expect exceed total sofia instal base
y/i yield annuiti year come critic new product thesi
sofia menu expans drive util per instrument
time addit progress significantli expand instal base connect
virena cloud infecti diseas tracker increas valu proposit sofia
custom cannib legaci quickvu revenu carri durabl razor/razor
blade revenu stream compani well better gross margin per kit final
larger instal base give substanti opportun cross-sel newli acquir
triag platform hospit custom believ carri signific strateg
valu last stand-alone poc oper scale left market reiter
ow rate
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidancecardiovascular/ toxicology/bnp busi mm given close updat model includ busi emb rev triag bnp model revenu contribut growthflu revenu mm forecast y/i modestli manag guidanc flu season track well previou year flu season infecti diseas mm similar flu infecti diseas product season respiratori season expect growth y/i driven strength strep diagnost mm mdx revenu includ solana amplivu lyra solana expect primari driver growth million expect revenu contribut repres estim growth low base eight fda approv solana assay though compani remain excit system confirmatori claim group strep instal basewith busi updat compani provid encourag feedback sofia total compani place cumul instrument aim hit encourag continu momentum sofia indic market share gain revenueour revenu estim assum sever flu season compar growth influenza growth primari driver due sever flu season growth close acquisit triage/bnp asset compani get one quarter contribut busi three quarter growthin manag guid toward double-digit growth legaci busi low-single-digit growth ebitda margin lt target cash ebitda margin driven new product growth leverag overhead expens complet notabl project follow acquisit triage/bnp expect hit target ratepro-forma tax rate benefit due triage/bnp intern mix addit manag note tax reform benefit rate epsadjust ep exclud stock-comp gross margin expect inclus million amort increment rent expens revenu expens expect rang includ amort expect repres revenu expect rang repurchasew expect cash flow gener focu debt repay follow triage/bnp statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight lead innov
point care poc test compani
leverag strength rapid infecti diseas
test build broader-bas diagnost platform
excit potenti sofia
penetr low-volum account also provid
compel solut address retail poc market
new product launch allow grow
market infecti diseas test take share
compani abl leverag infrastructur drive
synergi triag acquisit see upsid
share reflect upsid cash ep
risk pertain new molecular entrant
potenti take market share
infecti diseas test see downsid share
reflect downsid cash ep
pleas see report
earli call comeback
initi equal weight
intrigu mani part syneo health thesi cautiou
near-term outlook given challeng commerci segment coupl earli
natur inc research inventiv merger organ growth guidanc
call declin midpoint syneo guid mid-singl digit growth
includ m-hsd growth clinic segment rev flat growth
commerci segment cautiou commerci segment given recent trend
well cancel high-margin advertis contract septemb million
annual rev given on-going integr recent announc cfo greg
rush resign take cautiou view model organ growth
date tbadial-in tbapasscod tbametricjack commentarybarcguidancebarcguidancenet busi winswhil recent revenu growth compani clinic segment weaker histor trend compani new busi award solid syneo health achiev book-to-bil respect forecast step-up net new author less clinic revenue burn ratea clinic trial becom increasingli complex revenu burn rate decreas across cro industri model burn rate y/i model y/i slow compani burn rate revenu growth headwind organ growthweak clinic growth year-to-d attribut abnorm level delay two custom current cancel book compani believ could achiev upsid hsd ldd organ growth take conserv approach given merger integr risk model organ growth growth commerci organ weaker year syneo commerci segment annual organ revenu growth estim weak driven lower level drug approv cancel smaller cancel reduc spend compani largest advertis client advertis client headwind expect impact revenu offset stronger market environ higher level recent drug approv syneo guid toward flat growth commerci growth total organ growth forecast growth clinic declin commerci organ growth target compani initi guidanc msd import note greg rush compani cfo announc resign growth fxin line guidanc expect fx neutral revenu growth growthwith current forecast fx impact acquir growth expect total growth equat organ growth marginexpect cost synergi run-rat run-rat compani laid upsid case project ebitda margin expans predic compani abil off-set mix headwind compani advertis busi epsfollow complet merger inc research inventiv health compani provid guidanc earn ep forecast repres growth respect capital-expenditure forecast repres net debt-to-ttm ebitda expect syneo focu free cash flow debt repay near-term leverag compani abil use capit deploy meaning lever limit ebitda growth expect leverag expect see margin improv emb share repurchas model flowincom statement barclay life scienc tool diagnost
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight inc research inventiv
third largest cro largest provid commerci
solut merger creat opportun
complement offer two organ
drive revenu synergi said cautiou
around pro-forma leverag ttm ebitda
recent weak commerci solut
combin better commerci solut
segment growth cross-sel synergi drive
upsid ebitda forecast upsid case
repres upsid ebitda
oper execut merger integr
pressur new busi award earn growth
commerci solut segment
prolong weak downsid case
repres downsid ebitda
recent thought
see report
scientif patheon
iter unmatch
like setup thermo fisher head earn potenti upsid
organ acquir growth organ growth forecast consist
manag guidanc specif expect thermo fisher benefit
continu strength biopharma manufactur well rebound industri market
final remain bullish patheon acquisit see long runway ahead
thermo fisher aggreg share wallet biopharma custom compani
note puerto rico facil back run follow hurrican maria
guidanc assum would close full quarter overal think
recent result highlight durabl thermo fisher thesi
advantag allow compani drive consist result in-and-out cycl
et wednesday januari passcod n/ametricjack commentarybarcguidebarcguideorgan growthth calendar impact adjust workday impact model revenu growth midpoint long-term guidanc scienc solut lss follow strong organ adjust workday segment deceler growth growth due softer bioproduct growth affymetrix enter organ trend expect result consist growth project growth acceler easier comp acceler bioproduct instrument ai see opportun upsid ai segment industri exposur coverag seen posit order trend sinc model organ growth level growth would repres meaning improv organ growth notabl fei co enter organ growth calcul addit overal dx sd believ sd continu rel laggard model organ growth repres deceler expect growth improv forecast organ growth product servic lp comp get easier model organ growth versu model organ growth workday headwind expect drag growth expect patheon contribut fisher note fx expect headwind ep expect impact growthemb acquir growth partial year close affymetrix fei co finess informat patheon forecast emb growth margin adj forecast expans emb dilut patheon lower oper margin prior patheon deal manag guid expans thermo fisher increas ep guidanc midpoint account patheon better perfrom favor fx mm forecast reflect increas forecast repres revenu flat mm assum compani maintain annual dividend mm compani complet million share repurchas embed guidanc would expect less share repurchas activ de-lev statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight thermo fisher market leader
across divers portfolio life scienc tool
diagnost impress global reach across
custom class end market compani
consist track record organ growth capit
deploy manag execut
recommend share core hold exposur
innov healthcar
see upsid thermo fisher target
capit deploy better result
life acquisit upsid case reflect
upsid ebitda billion
thermo fisher exposur econom activ
end market could impact growth
downsid case reflect downsid
ebitda billion
believ underli demand driver across end market remain
consist repatri repres near-term opportun compani
biopharma revenu comp becom easier versu prior quarter
organ growth believ market look see growth
acceler us pharma sponsor china notabl contributor liquid
chromatographi demand countri look establish greater life scienc presenc
adopt western technolog academ govern market anoth
opportun compani look sustain strong result recent quarter
industri end market well-posit cyclic recoveri could
drive upsid thesi expect manag continu strategi share
repurchas use capit updat use cash tax reform top
mind cash trap oversea repres meaning opportun
et tuesday januari commentarybarcguidancebarcguidancebiopharma organ growthbiopharma lead growth driver given compani strength lc growth tie increas global pill count well larger popul access therapeut posit routin workflow qa/qc innov larger more-complex molecul drive demand character also benefit comp tough though believ sustain demand continu drive growth end market govern organ growth struggl rebound academ govern cite broad geograph strength rel peer compani exposur high-end instrument segment academ market thu great read rest coverag organ growthrevenu end market tend lumpi grow ex-fx ytd expect segment continu driven demand food end market quarter strong growth segment manag believ compani well-posit cyclic asia continu major growth driver growth driven strong result china japan asia largest geograph region term revenu benefit rise standard regul qualiti pharma healthcar appli set china revenu mix pharma food addit believ larg grow opportun chines tradit medicin n/an/an/an/aorgan instrument instrument sale lumpi instrument revenu grew organ basi benefit leadership lc well success new product launch instrument growth import indic futur consum servic organ growthopt impact two fewer workday extra day expect neutral revenu ep growthdur march investor day laid forecast mid-singl digit organ growth margin adj oper expens expect grow rate slower sale growth model expans compani oper margin alreadi highest amongst tool manag rais ep guidanc mid-point due mostli chang excess tax benfit stock comp solid result favor fx estim impli ep growth y/i net incom expans milford headquart spend closer normal rate move mm compani pay histor util toward buy-back compani assum repurchas facilit averag dilut share count million share statementcash barclay life scienc tool diagnost
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight admir track
record above-market revenu growth margin
given compani market domin
pharmaceut custom chromatographi
said balanc water success view
difficult gener sustain above-
market earn growth reflect
biopharma remain area strength higher
consum margin drive upsid
ebitda expect upsid ebitda
million yield upsid case
fund biotech pressur capit invest
life scienc tool drive downsid
ebitda estim downsid ebitda
million yield downsid case
valuat methodolog risk
valuat methodolog price target repres ebitda estim million
risk may imped achiev barclay research valuat price competit hereditari cancer test
busi primari concern new entrant look gain share decentr market away myriad addit compani
new product portfolio carri risk around commerci greater scrutini regul payor final reimburs remain
concern compani entir portfolio pressur price risk margin profit given fix cost natur myriad
valuat methodolog price target repres ebitda estim million multipl repres
higher multipl histor valuat believ warrant given compani recur revenu acceler growth profil
exposur person medicin
risk may imped achiev barclay research valuat price headwind experienc
hpv market serv cautiou remind price competit diagnost though reason believ special situat
mix track record set guidanc attribut volatil hpv diagnost compani also screen
exposur academ spend diagnost peer
valuat methodolog price target repres adjust cash ebitda estim million
risk may imped achiev barclay research valuat price acquisit triage/bnp carri merger
relat risk integr sell disrupt risk market rapid flu test could move molecular though
believ workflow issu continu favor immunoassay solut exhibit signific season volatil relat flu
season impact pace revenu growth profit cash flow rel lower barrier entri market
compar area diagnost
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
